Pulmonary hypertension in interstitial lung disease

International Journal of Clinical Practice

Volumn 62, Issue SUPPL.160, 2008, Pages 21-28

  Nathan, S D ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DISEASE SEVERITY; FIBROSING ALVEOLITIS; HISTIOCYTOSIS; HUMAN; INTERSTITIAL LUNG DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SURVIVAL TIME;

EID: 47349132624     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01624.x     Document Type: Review

References (52)

1. Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005 128 : 2393 9.
2. Lettieri CJ, Nathan SD, Barnett S, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Chest 2006 129 : 746 52.
3. Hamada K, Nagai S, Tanaka S et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007 131 : 650 6.
4. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007 131 : 657 63.
5. Nathan SD, Ahmad S, Koch J, Barnett S, Ad N, Burton N. Serial measures of pulmonary artery pressures in patients with idiopathic pulmonary fibrosis. Chest 2005 128 : 168S.
6. Ahmad S, Barnett SD, Shlobin OA, Nathan SD. Comparison of the prevalence of pulmonary arterial hypertension (PAH) in patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP). Am J Respir Crit Care Med 2006 3 : S242.
7. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005 25 : 783 8.
8. Handa T, Nagai S, Miki S et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006 129 : 1246 52.
9. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005 128 : 1483 9.
10. Nunes H, Humbert M, Capron F et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006 61 : 68 74.
11. Launay D, Mouthon L, Hachulla E et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007 34 : 1005 11.
12. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003 30 : 2398 405.
13. Dauriat G, Mal H, Thabut G et al. Lung transplantation for pulmonary langerhans cell histiocytosis: a multicenter analysis. Transplantation 2006 81 : 746 50.
14. Fartoukh M, Humbert M, Capron F et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000 161 : 216 23.
15. Chaowalit N, Pellikka PA, Decker PA et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary langerhans cell histiocytosis. Mayo Clin Proc 2004 79 : 1269 75.
16. Lupi-Herrera E, Sandoval J, Bialostozky D et al. Extrinsic allergic alveolitis caused by pigeon breeding at a high altitude. Am Rev Respir Dis 1981 124 : 602 7.
17. Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest 2001 120 : 1735 8.
18. Eder L, Zisman D, Wolf R, Bitterman H. Pulmonary hypertension and amyloidosis - an uncommon association: a case report and review of the literature. J Gen Intern Med 2007 22 : 416 9.
19. Odeh M, Oliven A, Misselevitch I, Boss JH. Acute cor pulmonale due to tumor cell microemboli. Respiration 1997 64 : 384 7.
20. Tomasini M, Chiappino G. Hemodynamics of pulmonary circulation in asbestosis: study of 16 cases. Am J Ind Med 1981 2 : 167 74.
21. Evers H, Liehs F, Harzbecker K et al. Screening of pulmonary hypertension in chronic obstructive pulmonary disease and silicosis by discriminant functions. Eur Respir J 1992 5 : 444 51.
22. Yildiz OA, Gulbay BE, Saryal S, Karabiyikoglu G. Evaluation of the relationship between radiological abnormalities and both pulmonary function and pulmonary hypertension in coal workers' pneumoconiosis. Respirology 2007 12 : 420 6.
23. Kramer MR, Estenne M, Berkman N et al. Radiation-induced pulmonary veno-occlusive disease. Chest 1993 104 : 1282 4.
24. Ebina M, Shimizukawa M, Shibata N et al. Heterogenous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004 169 : 1203 8.
25. Cosgrove GP, Brown KK, Schiemann WP et al. Pigment epithelial-derived factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004 170 : 242 51.
26. Burdick MD, Murray LA, Keane MP et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005 171 : 261 8.
27. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004 59 : 581 5.
28. Renzoni EA, Walsh DA, Salmon M et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003 167 : 438 43.
29. Gagermeier J, Dauber J, Yousem S, Gibson K, Kaminski N. Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. Chest 2005 128 : 601S.
30. Colombat M, Mal H, Groussard O et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Path 2007 38 : 60 5.
31. Craussman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996 153 : 426 35.
32. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005 25 : 783 8.
33. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003 62 : 97 9.
34. Nathan SD, Barnett SD, Saggar R et al. Echocardiography as a screening test of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2007 132 : 5428.
35. Leuchte HH, Neurohr C, Baumgartner R et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004 170 : 360 5.
36. Leuchte HH, Baumgartner RA, Nounou ME et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006 173 : 744 50.
37. Zisman DA, Karlamangla AS, Ross DJ et al. High-resolution chest computed tomography findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007 132 : 773 779.
38. McKay SA, Shlobin OA, Ahmad S, Barnett SD, Nathan SD. CAT scan correlation between pulmonary artery diameter and pulmonary artery pressure in idiopathic pulmonary fibrosis. Chest 2007 132 : 5582.
39. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000 162 : 1964 73.
40. Arcasoy SM, Christie JD, Ferrari VA et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003 167 : 735 40.
41. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002 360 : 895 900.
42. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary Fibrosis. Chest 2007 131 : 897 9.
43. Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999 160 : 600 7.
44. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001 120 : 866 72.
45. Fisher KA, Serlin DM, Wilson KC et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006 130 : 1481 8.
46. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2007 74 : 287 92.
47. Bonura E, Barnett CF, Barnett SD et al. Pulmonary hypertension secondary to sarcoidosis: potential role of therapy. Am J Respir Crit Care Med 2007 175 : A361.
48. Benyounes B, Crestani B, Couvelard A, Vissuzaine C, Aubter M. Steroid-responsive pulmonary hypertension in a patient with langerhans' cell granulomatosis (histiocytosis X). Chest 1996 110 : 284 6.
49. Ryu JH, Krowka MJ, Pellikka PA et al. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007 82 : 342 50.
50. Whelan TP, Dunitz JM, Kelly RF et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005 24 : 1269 74.
51. Saleem I, Moss J, Egan JJ. Lung transplantation for rare pulmonary diseases. Sarcoidosis Vasc Diffuse Dis 2005 22 : S85 90.
52. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis waiting lung transplantation. Chest 2003 124 : 922 8.